Literature DB >> 16275208

Clinical use of the Hamilton Depression Rating Scale: is increased efficiency possible? A post hoc comparison of Hamilton Depression Rating Scale, Maier and Bech subscales, Clinical Global Impression, and Symptom Checklist-90 scores.

Henricus G Ruhé1, Jack J Dekker, Jaap Peen, Rebecca Holman, Frans de Jonghe.   

Abstract

BACKGROUND: The 17-item Hamilton Depression Rating Scale (HDRS) is used as a semi-gold standard in research. In treatment guidelines, the HDRS measurements serve to determine response and remission and guide clinical decision making for nonresponders. However, its use in clinical practice is limited, possibly because the HDRS is time consuming. In addition, the multidimensional HDRS is criticized for not measuring a unidimensional aspect as depression severity. The Maier and the Bech, two 6-item severity subscales extracted from the HDRS, are relatively unknown. This paper investigates whether the measurements obtained with these subscales are comparable with the original HDRS measurements.
METHODS: Data from 2 randomized controlled trials in 482 male and female patients, diagnosed with a major depression (with or without dysthymia) according to Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition, of whom 219 participated in the trials, were reanalyzed. A standardized stepwise psychopharmacological treatment was compared with a combination of pharmacotherapy with Short Psychodynamic Supportive Psychotherapy in a psychiatric outpatient department. Outcome measures were internal consistency and concurrent validity of HDRS, Maier, Bech, Clinical Global Impression scales, and Symptom Checklist depression subscale. Effect sizes of HDRS, Maier, and Bech were used to compare measured treatment effects for the randomized subjects participating in the trials. Item Response Theory was used to obtain conversion tables for the HDRS, Maier, Bech, and Symptom Checklist depression subscale.
RESULTS: We found moderate internal consistency (Cronbach alpha approximately 0.6-0.7) and high correlations of the Maier and Bech subscales with overall HDRS scores. Overall, there were no clinically relevant differences in effect sizes between Maier, Bech, and HDRS, although some differences were statistically significant. Receiver operating characteristic curves showed no difference between Maier and Bech to define remission but showed the Clinical Global Impression ratings to be unreliable. A cutoff < or =4 corresponded with an HDRS < or =7 criterion in both subscales.
CONCLUSION: In clinical practice, both Maier and Bech scales can be used as equivalents of the HDRS, but will be more efficient.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16275208     DOI: 10.1016/j.comppsych.2005.03.001

Source DB:  PubMed          Journal:  Compr Psychiatry        ISSN: 0010-440X            Impact factor:   3.735


  18 in total

1.  Sensitivity to changes during antidepressant treatment: a comparison of unidimensional subscales of the Inventory of Depressive Symptomatology (IDS-C) and the Hamilton Depression Rating Scale (HAMD) in patients with mild major, minor or subsyndromal depression.

Authors:  Isabella Helmreich; Stefanie Wagner; Roland Mergl; Antje-Kathrin Allgaier; Martin Hautzinger; Verena Henkel; Ulrich Hegerl; André Tadić
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-09-30       Impact factor: 5.270

2.  Sertraline for Major Depression During the Year Following Traumatic Brain Injury: A Randomized Controlled Trial.

Authors:  Jesse R Fann; Charles H Bombardier; Nancy Temkin; Peter Esselman; Catherine Warms; Jason Barber; Sureyya Dikmen
Journal:  J Head Trauma Rehabil       Date:  2017 Sep/Oct       Impact factor: 2.710

3.  Dose-response relationship of duloxetine in placebo-controlled clinical trials in patients with major depressive disorder.

Authors:  Per Bech; Daniel K Kajdasz; Vibeke Porsdal
Journal:  Psychopharmacology (Berl)       Date:  2006-09-08       Impact factor: 4.530

4.  Rating depression over brief time intervals with the Hamilton Depression Rating Scale: standard vs. abbreviated scales.

Authors:  David A Luckenbaugh; Rezvan Ameli; Nancy E Brutsche; Carlos A Zarate
Journal:  J Psychiatr Res       Date:  2014-12-27       Impact factor: 4.791

5.  A randomized controlled trial of venlafaxine XR for major depressive disorder after spinal cord injury: Methods and lessons learned.

Authors:  Charles H Bombardier; Jesse R Fann; Catherine S Wilson; Allen W Heinemann; J Scott Richards; Ann Marie Warren; Larry Brooks; Catherine A Warms; Nancy R Temkin; Denise G Tate
Journal:  J Spinal Cord Med       Date:  2013-11-26       Impact factor: 1.985

Review 6.  Managing the patient with co-morbid depression and an anxiety disorder.

Authors:  Robert A Schoevers; Henricus L Van; Vincent Koppelmans; Simone Kool; Jack J Dekker
Journal:  Drugs       Date:  2008       Impact factor: 9.546

7.  Assessment of depressive symptom severity among patients with co-occurring bipolar disorder and substance dependence.

Authors:  Monika E Kolodziej; Margaret L Griffin; Rachel Bender; Roger D Weiss
Journal:  J Affect Disord       Date:  2007-06-28       Impact factor: 4.839

8.  Can a one-item mood scale do the trick? Predicting relapse over 5.5-years in recurrent depression.

Authors:  Gerard D van Rijsbergen; Claudi L H Bockting; Matthias Berking; Maarten W J Koeter; Aart H Schene
Journal:  PLoS One       Date:  2012-10-03       Impact factor: 3.240

9.  Effects of acupuncture on patients with fibromyalgia: study protocol of a multicentre randomized controlled trial.

Authors:  Jorge Vas; Manuela Modesto; Inmaculada Aguilar; Koldo Santos-Rey; Nicolás Benítez-Parejo; Francisco Rivas-Ruiz
Journal:  Trials       Date:  2011-02-28       Impact factor: 2.279

10.  Suicidal ideation during treatment of depression with escitalopram and nortriptyline in genome-based therapeutic drugs for depression (GENDEP): a clinical trial.

Authors:  Nader Perroud; Rudolf Uher; Andrej Marusic; Marcella Rietschel; Ole Mors; Neven Henigsberg; Joanna Hauser; Wolfgang Maier; Daniel Souery; Anna Placentino; Aleksandra Szczepankiewicz; Lisbeth Jorgensen; Jana Strohmaier; Astrid Zobel; Caterina Giovannini; Amanda Elkin; Cerisse Gunasinghe; Joanna Gray; Desmond Campbell; Bhanu Gupta; Anne E Farmer; Peter McGuffin; Katherine J Aitchison
Journal:  BMC Med       Date:  2009-10-15       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.